An Overview of Second-Generation Nanoparticles − Nano-structure Lipid Carrier Drug Delivery System
DOI:
https://doi.org/10.37285/ijpsn.2020.13.6.2Abstract
Lipids are used as vehicles for the preparation of various formulations prescribed for administrations, including emulsions, ointments, suspension, tablets, and suppositories. The first parental nano-emulsion was discovered in the 1950s, when it was added to the intravenous administration of lipid and lipid-soluble substances. Lipid-based drug delivery systems are important now-a-days. Solid nanoparticles (SLN) and Nanostructured lipid carriers (NLC) are very proficient due to the ease of production process, scale-up capability, bio-compatibility, the biodegradability of formulation components and other specific features of the proposed route. The administration or nature of the materials must be loaded into these delivery systems. The main objectives of this review are to discuss an overview of second-generation nanoparticles, their limitations, structures, and route of administration, with emphasis on the effectiveness of such formulations. NLC is the second generation of lipid nanoparticles having a structure like nanoemulsion. The first generation of nanoparticles was SLN. The difference between both is at its core. Both are a colloidal carrier in submicron size in the range of 40-1000 nm. NLC is the most promising novel drug delivery system over the SLN due to solving the problem of drug loading and drug crystallinity. Solid and liquid lipids combination in NLC formation, improve its quality as compare to SLN. NLC has three types of structures: random, amorphous, and multiple. The random structure containing solid-liquid lipids and consisting crystal and the liquid lipid irregular in shape; thereby enhance the ability of the lipid layer to pass through the membrane. The second is the amorphous structure. It is less crystalline in nature and can prevent the leakage of the loaded drug. The third type is multiple structures, which have higher liquid lipid concentrations than other types. The excipients used to form the NLC are bio-compatible, biodegradable and non-irritating, most of which can be detected using GRAS. NLC is a promising delivery system to deliver the drug through pulmonary, ocular, CNS, and oral route of administration. Various methods of preparation and composition of NLC influence its stability Parameters. In recent years at the educational level, the potential of NLC as a delivery mechanism targeting various organs has been investigated in detail
Downloads
Metrics
Keywords:
Nanostructured lipid carrier, Zeta potential, Homogenization, Crystallinity
Downloads
Published
How to Cite
Issue
Section
References
Chen Y, Pan L, Jiang M, Li D and Jin L (2016). Nanostructured lipid carriers enhance the bioavailability and brain cancer inhibitory efficacy of curcumin both in vitro and in vivo. Drug Deliv 23(4): 1383–1392.
Cheow WS and Hadinoto K (2011). Factors affecting drug encapsulation and stability of lipid–
polymer hybrid nanoparticles. Colloids Surf. B Biointerfaces. 85:214–220.
Cirri M, Maestrini L, Maestrelli F, Mennini N, Mura P, Ghelardini C and Mannelli LDC (2018). Design, characterization and in vivo evaluation of nanostructured lipid carriers (NLC) as a new drug delivery system for hydrochlorothiazide oral administration in pediatric therapy. Drug Deliver 25(1): 1910-1921.
El-Salamouni, NS, Farid RM, El-Kamel AH and El-Gamal SS (2015). Effect of sterilization on the physical stability of brimonidine-loaded solid lipid nanoparticles and nanostructured lipid carriers. Int. J. Pharm 496: 976–983.
Emami J, Rezazadeh M, Varshosaz J, Tabbakhian M and Aslani A (2012). Formulation of LDL Targeted Nanostructured Lipid Carriers Loaded with Paclitaxel: A Detailed Study of Preparation, Freeze Drying Condition, and In Vitro Cytotoxicity. Journal of Nanomaterials Article ID 358782:10 doi:10.1155/2012/358782.
Fang JY, Fang CL, Liu CH and Su YH (2008). Lipid nanoparticles as vehicles for topical psoralen delivery: solid lipid nanoparticles (SLN) versus nanostructured lipid carriers (NLC). Eur. J. Pharm. Biopharm 70(2): 633–640.
Intakhab AM, Baboota S, Ahuja A, Ali M, Ali J and Sahni JK (2013). Intranasal infusion of nanostructured lipid carriers (NLC) containing CNS acting drug and estimation in brain and blood. Drug Deliv 20(6): 247–251.
Intakhab AM, Baboota S, Ahuja A, Ali M, Ali J and Sahni JK (2014). Aseem Bhatnagar. Pharmacoscintigraphic evaluation of potential of lipid nanocarriers for nose-to-brain delivery of antidepressant drug. International Journal of Pharmaceutics 470: 99–106.
Intakhab AM, Beg S, Samad A, Baboota B, Kohli K, Ali J, Ahuja A and Akbar M (2010). Strategy for effective brain drug delivery. European Journal of Pharmaceutical Sciences 40: 385–403.
Intakhab AM, Beg S, Ahuja A, Ali M, Ali J and Sahni JK (2012). Intranasal administration of nanostructured lipid carriers containing CNS acting drug: Pharmacodynamic studies and estimation in blood and brain. Journal of Psychiatric Research 46:1133e1138.
Jain K, Sood S and Gowthamarajan K (2015). Optimization of artemetherloaded NLC for intranasal delivery using central composite design. Drug Deliv 22(7): 940–954.
Jores K, Haberland A, Wartewig S and Mader K (2005). Solid lipid nanoparticles (SLN) and oil-loaded SLN studied by spectrofluorometry and Raman spectroscopy. Pharm. Res. 22 (11):1887–1897.
Khan S, Shaharyar M, Fazil M, and Baboota S (2016). Tacrolimus-loaded nanostructured lipid carriers for oral delivery - optimization of production and characterization, Eur. J. Pharm. Biopharm.108: 277–288.
Khosaa A, Reddi S and Saha RN (2018). Nanostructured lipid carriers for site-specific drug delivery. Biomedicine & Pharmacotherapy 103: 598–613.
Lim WM, Rajinikanth PS and Mallikarjun C (2014). Formulation and delivery of itraconazole to the brain using a nanolipid carrier system. Int. J. Nanomed 9: 2117–2126.
Lin CH, Chen CH, Lin ZC and Fang JY (2017). Recent advances in oral delivery of drugs and bioactive natural products using solid lipid nanoparticles as the carriers. J. Food. Drug Anal. 25 (2):219–234.
Lopez GR and Ganem RA (2015). Solid Lipid Nanoparticles (SLN) an Nanostructured Lipid Carriers (NLC): Occlusive Effect and Penetration Enhancement Ability. Journal of Cosmetics, Dermatological Sciences and Applications 5: 62-72.
Mandpe L and Pokharkar V (2013). Targeted brain delivery of Iloperidone nanostructured lipid carriers following intranasal administration: in vivo pharmacokinetics and brain distribution studies. J. Nanopharm Drug Deliv 1(2): 212–225.
Mehnert W and Mäder K (2001). Solid lipid nanoparticles: production, characterization and applications. Adv. Drug Deliv. Rev 47 (2):165–196.
Muller RH, Petersen RD, Hommoss A and Pardeike J (2007). Nanostructured lipid carriers (NLC) in cosmetic dermal products. Advanced Drug Delivery Reviews 59:522–530.
Owen YC, Claudia M, Angelica MDSS, Janet W, Lucia AR, Susanne N, Joseph PH and Martin EP (2012). Intranasally applied l- DOPA alleviates parkinsonian symptoms in rats with unilateral nigro-striatal 6-OHDA lesions. Brain Research Bulletin 87:340– 345.
Piao H, Ouyang M, Xia D, Quan P, Xiao W, Song Y and Cui F (2011). In vitro-in vivo study of CoQ10-loaded lipid nanoparticles in comparison with nanocrystals. Int. J. Pharm 419: 255–259.
Pinheiro M, Ribeiro R, Vierira A, Andrade F and Reis S (2016) . Design of a nanostructured lipid carrier intended to improve the treatment of tuberculosis. Drug Design Development and Therapy 10: 2467-2475.
Qianwen Li, Tiange C, Yinghong H, Xi X, Susan PCC and Yu C (2017). A Review of the Structure, Preparation, and Application of NLCs, PNPs, and PLNs. Nanomaterials 7: 122.
Shah R, Eldridge D and Palombo E (2015). Lipid Nanoparticles: Production, Characterization and Stability. Pharmaceutical Science & Drug Development DOI 10.1007/978-3-319-10711-0_2:11–22
Sharma S, Lohan S and R. Murthy SR. Formulation and characterization of intranasal mucoadhesive nanoparticulates and thermo-reversible gel of levodopa for brain delivery. Drug Dev Ind Pharm. Early Online: 1–10.
Sanchez-Lopez E and M. Espina SD (2017). Lipid nanoparticles (SLN, NLC): overcoming the anatomical and physiological barriers of the eye part II: ocular drug-loaded lipid nanoparticles. Eur. J. Pharm. Biopharm 110: 58–69.
Singh SK, Dadhania P, Vuddanda PR and Jain A (2016). Intranasal delivery of asenapine loaded nanostructured lipid carriers: formulation, characterization, pharmacokinetic and behavioural assessment. RSC Adv 6(3): 2032–2045.
Siti S, Effionora A, Mahdi D and Umi C (2017). Preparation and Characteristics of Nanostructured Lipid Carrier (NLC) Loaded Red Ginger Extract Using High Pressure Homogenizer Method. J. Pharm. Sci. & Res 9(10): 1889-1893.
Sofia J, Pamudji, Mauludin R and Nasya I (2016). Development of Nanostructured Lipid Carrier Formulation Containing of Retinyl Palmitate. Int J Pharm Pharm Sci 8(2): 256-260.
Song S, Mao G, Du J and Zhu X (2016). Novel RGD containing, temozolomide-loading nanostructured lipid carriers for glioblastoma multiforme chemotherapy. Drug Deliv 23 (4):1404–1408.
Tae KK, Wonku K, In Koo C, Seaung YO, Yeon HL and Hye SG (2009). Pharmacokinetic evaluation and modeling of formulated levodopa intranasal delivery systems. European Journal of Pharmaceutical Sciences 38: 525–532.
Tran T H, Ramasamy T, Truong DH, Choi HG, Yong CS and Kim JO (2014). Preparation and characterization of Fenofibrate- loaded Nanostructured Lipid Carrier for oral bioavailability Enhancement. American Association of pharmaceutical scientists. 1530-9932/14/0000-0001/0.
Tsai MJ., Wu PC, Huang YB, Chang JS and Lin CL (2012). Baicalein loaded in tocol nanostructured lipid carriers (tocol NLCs) for enhanced stability and brain targeting. Int. J. Pharm 423(2): 461–470.
Uner M. (2016). Characterization and imaging of solid lipid nanoparticles and nanostructured lipid carriers. In Handbook of Nanoparticles (Aliofkhazraei M ed.), Springer International Publishing, pp 117–141.
Vandana SN, Laxman AK, Shankar SZ, Pranita PD and Priyanka SP (2014). Ameliorative Effect of Nebivolol in Parkinson’s disease. Erican Journal of Pharmacology and Pharmacotherapeutics 1(3): 116-126.
Ur Rehman A, Collot M, S. Klymchenko A, Akram S, Mustafa B, Vandamme T and Anton N (2019). Spontaneous nano- emulsion with tailor –made amphiphilic polymers and related monomers. European journal of pharmaceutical research 1(1): 27-36.
Wavikar PR and Vavia PR (2015). Rivastigmine-loaded in situ gelling nanostructured lipid carriers for nose to brain delivery. J. Liposome Res 25(2): 141–149.
Wei H, Huating D, Houjiu W, Zhigao S, Hua W and Linhua H (2017). Preparation and Characterisation of Nobiletin-Loaded Nanostructured Lipid Carriers. Journal of Nanomaterials Article ID 2898342, 10 pages. DOI.org/10.1155/2017/2898342.
